Clinical Trial

FusionVAC22_01: Fusion Transcript-based Peptide Vaccine Combined with Immune Checkpoint Inhibition

Study acronym: FusionVAC22
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The aim of this clinical trial is to evaluate the immunogenicity along with safety and toxicity as well as first efficacy of a DNAJB1-PRKACA fusion transcript-based peptide vaccine (Fusion-VAC-XS15) in combination with anti-programmed cell death-ligand 1 immune checkpoint inhibition (ICI) by Atezolizumab (TecentriqTM) in patients with Fibrolamellar hepatocellular carcinoma (FL-HCC) or other cancer entities carrying the DNAJB1-PRKACA fusion transcript.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-06-29; most recent amendment 2024-12-04.
Status change: Not Yet Recruiting → Recruiting 2023-09-27
Trial Details
NCT Number NCT05937295
Lead Sponsor University Hospital Tuebingen
Conditions Fibrolamellar Hepatocellular Carcinoma
Enrollment 20 participants
Start Date 2023-09-26
Primary Completion 2026-09 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2024-12-09